Mosaic Biosciences launches SortAI, a wet lab validation service built for ai-designed antibody libraries. Mosaic Biosciences today announced the commercial launch of SortAI, a yeast display-based validation service designed specifically for AI-generated antibody sequence panels. SortAI enables AI drug discovery companies to screen model-derived libraries before committing to full recombinant protein production, returning structured experimental data that feeds directly back into model retraining. The bottleneck AI drug discovery can't ignore. Generative AI platforms are transforming antibody drug design, producing campaigns of hundreds of thousands to millions of computationally designed sequences per cycle. Yet the infrastructure built to validate those sequences was designed around traditional single-candidate drug programs: full recombinant expression on every sequence, one at a time. The result is a compounding problem: slow cycles, wasted production budget, and models that cannot improve until the wet lab catches up. Typical CROs produce and characterize whatever sequence list arrives in their inbox. SortAI filters it first. "Generative models can produce thousands of antibody candidates. Wet labs can validate a fraction of them. SortAI triages AI-generated libraries at scale so your best sequences get tested first and nothing falls through." - Eric Furfine, PhD, Chief Scientific Officer, Mosaic Biosciences One engagement. The full triage picture. SortAI delivers a complete triage picture in a single defined engagement: Binding, affinity, epitope binning, developability, and function together: A complete discovery funnel in a single engagement, with deliverables structured for model retraining rather than drug program documentation. Sequence liability review at intake: Mosaic scientists screen panels for CDR liabilities, aggregation motifs, poor expression signals, and other flags most AI algorithms don't account for. Bad sequences are removed before they waste wet lab capacity. Yeast-based selection at library scale: Multi-round selection across panels ranging from hundreds to over millions of sequences, with next-generation sequencing (NGS) at each round to track full population dynamics. Negative data returned as a deliverable: Every selection round generates a negative population. SortAI sequences and returns those alongside ranked positive binders - because what didn't bind is half the training signal. Function pulled forward: Candidates that pass binding are immediately pressure-tested through cell-based functional screening, before expensive downstream development work begins. Binding, affinity, epitope binning, developability, and function together: A complete discovery funnel in a single engagement, with deliverables structured for model retraining rather than drug program documentation. Faster cycles. A fraction of the cost. A production-centric competitor workflow covering binding and affinity alone requires approximately 7 weeks and costs significantly more than a full SortAI engagement, which extends through developability profiling and cell-based functional screening. Sequence enrichment for model training is available as early as 6 weeks from project initiation; a full engagement completes in approximately 14 weeks. The yeast display platform underpinning SortAI scales to 10[7] sequence diversity, three orders of magnitude beyond the throughput of production-centric validation workflows, enabling functional triage at the true scale of AI-generated libraries. "AI companies need data that makes the next design cycle better, not just data that's fast. SortAI is built on the principle that quality of signal matters more than speed of throughput, and that the two aren't mutually exclusive." - Tracey Mullen, Chief Strategy Officer, Mosaic Biosciences Built on demonstrated capability. SortAI is backed by Mosaic's team of 50+ scientists, 80% holding advanced degrees and more than 216 completed discovery programs. The yeast display workflow that powers SortAI has already demonstrated results in library-based screening engagements that competing CROs were unable to accommodate. The platform was first introduced publicly at PEGS Boston 2026 and is now available as a defined commercial service. Detailed pricing and scope information is available upon request under NDA. About Mosaic Biosciences. Mosaic Biosciences is a biologics discovery company specializing in antibody and protein engineering, with expertise spanning transgenic mouse platforms, display technologies, and multispecific antibody formats. Mosaic partners with biotech and pharmaceutical companies to generate high-quality, developable biologics optimized for real-world therapeutic success.

Mosaic Biosciences expands discovery capabilities with carterra(r) High-Throughput SPR platform. Distributed by EIN Presswire Mosaic Biosciences announces the addition of a Carterra (HT-SPR) instrument to its discovery platform for characterization and enhanced discovery capabilities. BOULDER, CO, UNITED STATES, March 26, 2026 /EINPresswire.com/ - Mosaic Biosciences, a leader in protein and antibody therapeutic discovery, today announced the addition of a Carterra high-throughput surface plasmon resonance (HT-SPR) instrument to its discovery platform. This addition of characterization technology strategically enhances Mosaic's discovery capabilities by integrating industry-leading real-time kinetic analysis and epitope binning into its existing discovery and engineering workflows. The Carterra LSAXT HT-SPR instrument enables rapid, high-sensitivity monitoring and analysis of protein-protein and antibody-antigen interactions with unparalleled throughput driving efficiency in lead identification, optimization, and candidate selection in a single workflow. With this technology, Mosaic will accelerate the pace at which it discovers and develops differentiated biologics across multiple therapeutic areas, including oncology, immunology, and rare diseases. "As we scale our antibody and protein discovery engine, this acquisition reinforces Mosaic's commitment to delivering high-quality therapeutic candidates faster and with deeper mechanistic insight," said Tracey Mullen, Chief Strategy Officer at Mosaic Biosciences. "The Carterra platform's ability to generate rich binding data at scale, including best-in-class kinetics, and epitope binning directly complements our integrated engineering and discovery strategy." The addition of the Carterra platform expands Mosaic's internal capabilities by enabling: - High-throughput kinetic measurements across extensive candidate libraries - Epitope binning to group candidates and prioritize binding sites with functional relevance - Rapid characterization workflows that feed robust data into Mosaic's computational models and decision frameworks This newly acquired technology will be incorporated into Mosaic's discovery pipelines immediately, strengthening collaborative programs with partners and bringing deeper biophysical insight earlier into discovery programs, enabling more informed candidate selection and de-risked advancement. "We are delighted to support Mosaic Biosciences in leveraging Carterra's HT-SPR technology to advance its mission of discovering transformative therapeutics," said Chris Silva, Vice President of Marketing and Product at Carterra. "By combining Carterra's unmatched throughput and data fidelity with their innovative discovery platform, Mosaic stands to make a meaningful impact on drug discovery." About Mosaic Biosciences Mosaic Biosciences is a biologics discovery company specializing in antibody and protein engineering, with expertise spanning transgenic mouse platforms, display technologies, and multispecific antibody formats. Mosaic partners with biotech and pharmaceutical companies to generate high-quality, developable biologics optimized for real-world therapeutic success. To learn more visit www.mosaicbio.com About Carterra, Inc. Carterra(R) is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Since the Company's first product launch in 2018, its Surface Plasmon Resonance (SPR) platforms have been adopted by the largest 20 pharmaceutical companies, major CROs, and leading biotechs across the world. Carterra's high throughput LSA, LSAXT, Ultra, and Vega platforms transform label-free characterization workflows, enabling screening and characterization for both large and small molecules in a single step. The instruments combine patented microfluidics technology with real-time High-Throughput SPR (HT-SPR) and industry-leading analysis and visualization software - delivering up to 100 times the data in 10% of the time, while using only 1% of the sample compared to existing label-free platforms. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Nashville, Manchester (England), and Munich (Germany). Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. Carterra, Inc. Cheri Salazar (408) 594-9400 [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]

As part of its commitment to transparency, Mosaic Biosciences launched the Frontier Fields program to document real farmers' experiences and honest opinions of biologicals during the 2024 growing season.